Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes

What this study is testing ClinicalTrials.gov NCT04307797 ↗

Description as written by the study sponsor.

The study seeks to explore the cardiovascular effects of co-agonism at the glucagon and (glucagon-like peptide-1) GLP-1 receptor. Glucagon and exenatide will be intravenously infused into participants with type 2 diabetes (T2DM). Overall, the aim of the study is to further the investigator's understanding on the role these endogenous substances have on normal cardiac physiology, myocardial energetics and myocardial glucose uptake through a series of PET and MRI imaging studies

Treatments tested

• 0.9% Sodium-chloride Drug

  Part A - 0.9% saline infusion during cardiac PET-MRI scan

• Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min also known as Byetta Drug

  Part A - exenatide and glucagon infusion during cardiac PET-MRI scan

• Glucagon 12.5ng/kg/min and 0.9% saline Drug

  Part A - Glucagon and 0.9% saline infusion during PET-MRI scan

• 0.9% Sodium-chloride Drug

  Part B - 0.9% saline infusion during 7T 31P MRS scan

• Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min Drug

  Part B - exenatide and glucagon infusion during 7T 31P MRS scan

• Glucagon 12.5ng/kg/min Drug

  Part B - Glucagon infusion during 7T 31P MRS scan